In people with a suboptimal clinical response after MBS, semaglutide results in substantial and clinically significant body weight reduction along with improvement in metabolic parameters and quality of life, compared to placebo @NatureMedicine https://t.co/cro9e2B9aQ
Donโt miss this great opportunity! Excited for the upcoming โCoffee with the Expertโ session with @JaimeAlmandoz
If youโre interested in obesity medicine, research, or academic mentorship, this is a session you wonโt want to miss! โ๏ธ
@ObesitySociety@UTSWInternalMed
Another excellent #DDW2026
Great connecting with colleagues, collaborators & industry partners on advancing liver & metabolic health, expanding clinical trial access, & improving patient care
Thanks to all who took the time to meet with @TexasLiverCare & @EvidentisHQ in Chicago
Proud to showcase the incredible work from @UTSWGI at @DDWMeeting! ๐ฅ
๐ 50+ lectures & posters ๐ค ๐
๐ Faculty, fellows, and trainees leading innovation in GI ๐ง
Join us in Chicago and follow along as we share advances in hepatology, IBD, GI oncology, and beyond ๐ซ
Proud to share our latest @AlcHepNet work in @ACERjournal
https://t.co/dXGaOz0Gd8
Among 518 survivors of alcohol-associated hepatitis, >20% returned to drinking by 3 months
AH care must integrate early, proactive AUD treatment
Supports @NIAAAnews ITAALD study rationale
Phosphatidylethanol (PEth) predicts hepatic decompensation independently of NITs in those at risk of alcohol-related liver disease. Repeated PEth sustains prognostic utility.
๐ https://t.co/0deS5ZFtuR
@NikolajTorp@AleksanderKrag@IsraelsenMads @MajaThiele
As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance.
A new Practice Guidance update in @HEP_Journal provides evidence-based recommendations on using semaglutide therapy for MASH, including patient selection, comorbidity management, and monitoring strategies.
๐ View the update: https://t.co/vMjvwAmxoO
So lucky to have worked with my good friend @gioroldanc
This is great work, so proud of you
Clostridioides difficile Infection Among Hospitalized Patients With Cancer https://t.co/uwHREPIReT
The IARC Working Group summarizes guidance on ๐. ๐ฑ๐บ๐ญ๐ฐ๐ณ๐ช screen-and-treat programs for gastric cancer prevention and concludes that prevention is the most effective strategy amid a rising global burden. Learn more: https://t.co/fyqf8Zd0RV
#LFNpearls By: @sarachapinMD
โญ๏ธ Immunosuppression after liver transplant: simple in concept, complex in practice.
โญ๏ธ How do you balance rejection, renal function, and malignancy risk?
๐ https://t.co/HMjxpvq1hT